$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx

$bcrx Overview Financials Valuation SEC Filings Company Website

2014 Q4 Form 10-K Financial Statement

#000117184316008207 Filed on February 26, 2016

Income Statement

Concept	2014 Q4	2014 Q3	2014 Q2
Revenue	$5.446M	$3.238M	$1.466M
YoY Change	-48.46%	35.54%	78.56%
Cost Of Revenue	$40.00K
YoY Change	100.0%
Gross Profit	$5.400M	$3.238M	$1.466M
YoY Change	-48.82%	35.48%	78.78%
Gross Profit Margin	99.16%	100.0%	100.0%
Selling, General & Admin	$2.050M	$1.810M	$2.010M
YoY Change	-0.49%	35.07%	40.56%
% of Gross Profit	37.96%	55.9%	137.11%
Research & Development	$18.51M	$13.04M	$11.07M
YoY Change	24.81%	63.42%	-4.02%
% of Gross Profit	342.78%	402.59%	754.91%
Depreciation & Amortization	$40.00K	$40.00K	$50.00K
YoY Change	-20.0%	-42.86%	-37.5%
% of Gross Profit	0.74%	1.24%	3.41%
Operating Expenses	$20.56M	$13.04M	$11.07M
YoY Change	21.8%	63.42%	-14.61%
Operating Profit	-$15.16M	-$11.61M	-$11.62M
YoY Change	139.49%	67.65%	-4.29%
Interest Expense	$3.480M	$1.217M	$1.225M
YoY Change	282.42%	2.18%	-4183.33%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$11.67M	-$8.730M	-$14.65M
YoY Change	114.92%	9.13%	20.38%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$11.67M	-$8.731M	-$14.65M
YoY Change	114.99%	9.12%	20.35%
Net Earnings / Revenue	-214.32%	-269.64%	-999.25%
Basic Earnings Per Share			-$0.23
Diluted Earnings Per Share	-$162.3K	-$121.6K	-$0.23
COMMON SHARES
Basic Shares Outstanding			63.65M
Diluted Shares Outstanding		71.80M	63.65M

Balance Sheet

Concept	2014 Q4	2014 Q3	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$72.77M	$127.1M	$132.1M
YoY Change	91.23%	198.42%	353.95%
Cash & Equivalents	$54.54M	$121.2M	$121.5M
Short-Term Investments	$18.23M	$6.000M	$10.60M
Other Short-Term Assets	$6.400M	$4.700M	$5.200M
YoY Change	236.84%	147.37%	52.94%
Inventory	$683.0K
Prepaid Expenses
Receivables	$9.500M	$3.200M	$900.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$89.34M	$135.1M	$138.3M
YoY Change	112.11%	188.43%	312.84%
LONG-TERM ASSETS
Property, Plant & Equipment	$207.0K	$200.0K	$200.0K
YoY Change	-32.35%	-44.29%	-50.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$41.10M	$300.0K	$600.0K
YoY Change	1480.77%	-57.14%
Other Assets	$6.031M	$1.500M	$2.900M
YoY Change	66.6%	-70.44%	-51.67%
Total Long-Term Assets	$47.53M	$2.000M	$3.700M
YoY Change	604.68%	-68.58%	-42.19%
TOTAL ASSETS
Total Short-Term Assets	$89.34M	$135.1M	$138.3M
Total Long-Term Assets	$47.53M	$2.000M	$3.700M
Total Assets	$136.9M	$137.1M	$142.0M
YoY Change	180.1%	157.68%	255.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.849M	$2.300M	$2.400M
YoY Change	-31.74%	85.33%	140.0%
Accrued Expenses	$11.33M	$16.10M	$11.10M
YoY Change	97.3%	109.96%	18.09%
Deferred Revenue
YoY Change
Short-Term Debt	$30.00M	$30.00M	$30.00M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$57.29M	$49.80M	$44.90M
YoY Change	275.54%	277.79%	274.17%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Other Long-Term Liabilities	$3.900M	$3.800M	$6.900M
YoY Change	-17.02%	-42.42%	-1.43%
Total Long-Term Liabilities	$3.900M	$3.800M	$6.900M
YoY Change	-88.76%	-89.62%	-81.35%
TOTAL LIABILITIES
Total Short-Term Liabilities	$57.29M	$49.80M	$44.90M
Total Long-Term Liabilities	$3.900M	$3.800M	$6.900M
Total Liabilities	$61.20M	$53.70M	$51.90M
YoY Change	22.4%	7.83%	5.92%
SHAREHOLDERS EQUITY
Retained Earnings	-$467.9M
YoY Change	10.69%
Common Stock	$720.0K
YoY Change	-99.83%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$75.64M	$83.50M	$90.10M
YoY Change
Total Liabilities & Shareholders Equity	$136.9M	$137.1M	$142.0M
YoY Change	180.1%	157.68%	255.89%

Cashflow Statement

Concept	2014 Q4	2014 Q3	2014 Q2
OPERATING ACTIVITIES
Net Income	-$11.67M	-$8.731M	-$14.65M
YoY Change	114.99%	9.12%	20.35%
Depreciation, Depletion And Amortization	$40.00K	$40.00K	$50.00K
YoY Change	-20.0%	-42.86%	-37.5%
Cash From Operating Activities	-$13.89M	-$8.600M	-$7.100M
YoY Change	207.98%	8.45%	145.67%
INVESTING ACTIVITIES
Capital Expenditures	-$70.00K	-$30.00K	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$53.02M	$4.900M	$9.270M
YoY Change	2246.02%	-184.34%	262.11%
Cash From Investing Activities	-$53.09M	$4.870M	$9.260M
YoY Change	2249.12%	-183.82%	266.01%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$115.0M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	360.0K	3.380M	105.8M
YoY Change	-80.95%	-83.11%	1884.43%
NET CHANGE
Cash From Operating Activities	-13.89M	-8.600M	-7.100M
Cash From Investing Activities	-53.09M	4.870M	9.260M
Cash From Financing Activities	360.0K	3.380M	105.8M
Net Change In Cash	-66.62M	-350.0K	107.9M
YoY Change	1265.16%	-105.58%	2071.63%
FREE CASH FLOW
Cash From Operating Activities	-$13.89M	-$8.600M	-$7.100M
Capital Expenditures	-$70.00K	-$30.00K	$0.00
Free Cash Flow	-$13.82M	-$8.570M	-$7.100M
YoY Change	206.43%	8.07%	148.25%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2015Q4	bcrx	Accrued Inventory Expense AccruedInventoryExpense	549000
CY2014Q4	bcrx	Accrued Inventory Expense AccruedInventoryExpense	397000
CY2015Q4	bcrx	Available For Sale Securities Accrued Interest AvailableForSaleSecuritiesAccruedInterest	293000
CY2014Q4	bcrx	Available For Sale Securities Accrued Interest AvailableForSaleSecuritiesAccruedInterest	179000
CY2015Q4	bcrx	Available For Sale Securities Debt Maturities After One Through Two Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue	28395000
CY2014Q4	bcrx	Available For Sale Securities Debt Maturities After One Through Two Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue	25459000
CY2015Q4	bcrx	Available For Sale Securities Debt Maturities Maturing After Two Years AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears	19288000
CY2014Q4	bcrx	Available For Sale Securities Debt Maturities Maturing After Two Years AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears	15657000
CY2015	bcrx	Collaborative And Other Research And Development CollaborativeAndOtherResearchAndDevelopment	39580000
CY2014	bcrx	Collaborative And Other Research And Development CollaborativeAndOtherResearchAndDevelopment	10550000
CY2013	bcrx	Collaborative And Other Research And Development CollaborativeAndOtherResearchAndDevelopment	14769000
CY2015	bcrx	Collaborative And Other Research And Development Revenues CollaborativeAndOtherResearchAndDevelopmentRevenues	39580000
CY2014	bcrx	Collaborative And Other Research And Development Revenues CollaborativeAndOtherResearchAndDevelopmentRevenues	10550000
CY2013	bcrx	Collaborative And Other Research And Development Revenues CollaborativeAndOtherResearchAndDevelopmentRevenues	14769000
CY2014Q2	bcrx	Common Stock To Be Issued Value CommonStockToBeIssuedValue	70000000
CY2015Q4	bcrx	Deferred Collaboration Expense Assets DeferredCollaborationExpenseAssets	265000
CY2014Q4	bcrx	Deferred Collaboration Expense Assets DeferredCollaborationExpenseAssets	177000
CY2015	bcrx	Deferred Collaboration Expense Changes In Operating Assets And Liabilities DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities	102000
CY2014	bcrx	Deferred Collaboration Expense Changes In Operating Assets And Liabilities DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities	-59000
CY2013	bcrx	Deferred Collaboration Expense Changes In Operating Assets And Liabilities DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities	-5133000
CY2015	bcrx	Effective Income Tax Rate Reconciliation Tax Credit Orphan Drug Amount EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount	4307000
CY2014	bcrx	Effective Income Tax Rate Reconciliation Tax Credit Orphan Drug Amount EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount
CY2013	bcrx	Effective Income Tax Rate Reconciliation Tax Credit Orphan Drug Amount EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount
CY2015	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized For Remainder Of Fiscal Year EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear	7023000
CY2015	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Four EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour	1683000
CY2015	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Three EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree	3891000
CY2015	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Two EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo	6010000
CY2015	bcrx	Income Tax Reconciliation Income Tax Expense Benefit Expiration Of Carry Forwards IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards	330000
CY2014	bcrx	Income Tax Reconciliation Income Tax Expense Benefit Expiration Of Carry Forwards IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards	373000
CY2013	bcrx	Income Tax Reconciliation Income Tax Expense Benefit Expiration Of Carry Forwards IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards	242000
CY2015Q4	bcrx	Lease Financing Obligation Net Of Current LeaseFinancingObligationNetOfCurrent	2375
CY2015	bcrx	Sharebased Compensation Arrangement By Sharebased Payment Award Options Forfeitures In Period Awards Available SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable	33000
CY2013Q3	bcrx	Stock Issued During Period Shares For Over Allotment Option Exercised By Underwriter StockIssuedDuringPeriodSharesForOverAllotmentOptionExercisedByUnderwriter	600000
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9307000
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2849000
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16237000
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11329000
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	242000
CY2014Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	238000
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14205000
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14025000
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-206000
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-130000
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	558113000
CY2014Q4	bcrx	Lease Financing Obligation Net Of Current LeaseFinancingObligationNetOfCurrent
CY2015Q1	bcrx	Maximum Aggregate Offering Price MaximumAggregateOfferingPrice	150000000
CY2013Q4	bcrx	Maximum Aggregate Offering Price MaximumAggregateOfferingPrice	125000000
CY2015	bcrx	Number Of Stockbased Compensation Plans NumberOfStockbasedCompensationPlans	2
CY2015	bcrx	Receipt Payment Of Foreign Currency Derivative Collateral ReceiptPaymentOfForeignCurrencyDerivativeCollateral
CY2014	bcrx	Receipt Payment Of Foreign Currency Derivative Collateral ReceiptPaymentOfForeignCurrencyDerivativeCollateral
CY2013	bcrx	Receipt Payment Of Foreign Currency Derivative Collateral ReceiptPaymentOfForeignCurrencyDerivativeCollateral	5180000
CY2013Q4	bcrx	Remaining Aggregate Offering Price RemainingAggregateOfferingPrice	10000000
CY2013Q4	bcrx	Securities Offered SecuritiesOffered	10000000
CY2013	bcrx	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Awards Available ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable	3277000
CY2014	bcrx	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Awards Available ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable	1965000
CY2015	bcrx	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Awards Available ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable	2217000
CY2013	bcrx	Sharebased Compensation Arrangement By Sharebased Payment Award Options Forfeitures In Period Awards Available SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable	1801000
CY2014	bcrx	Sharebased Compensation Arrangement By Sharebased Payment Award Options Forfeitures In Period Awards Available SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable	88000
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	542943000
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4368000
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10177000
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9705000
CY2015	us-gaap	Advertising Expense AdvertisingExpense	103000
CY2014	us-gaap	Advertising Expense AdvertisingExpense	290000
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9705000
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10177000
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4368000
CY2015	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	439000
CY2013	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	439000
CY2014	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	439000
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3524000
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3991000
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1430000
CY2015Q4	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	32000
CY2015Q4	us-gaap	Assets Assets	124555000
CY2014Q4	us-gaap	Assets Assets	136874000
CY2015Q4	us-gaap	Assets Current AssetsCurrent	65990000
CY2014Q4	us-gaap	Assets Current AssetsCurrent	89343000
CY2015Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	70347000
CY2014Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	59348000
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5000
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5000
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	212000
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	133000
CY2015Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	70261000
CY2014Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	59297000
CY2015Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	22664000
CY2014Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	18232000
CY2015Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	22664000
CY2014Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	18232000
CY2015Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	47683000
CY2014Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	41116000
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28899000
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54540000
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21164000
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20891000
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-25641000
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	33376000
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	273000
CY2014Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2285000
CY2015Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	329000
CY2014Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	394000
CY2015Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	9674000
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	3552000
CY2015Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	4240000
CY2014Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	3798000
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	720000
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-43095000
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	73355000
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	71955000
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	73355000
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	71955000
CY2011Q3	us-gaap	Common Stock Value CommonStockValue	70000000
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	734000
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-45323000
CY2013	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-30131000
CY2015	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1368000
CY2014	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1000
CY2013	us-gaap	Cost Of Goods Sold CostOfGoodsSold
CY2015	us-gaap	Costs And Expenses CostsAndExpenses	87701000
CY2014	us-gaap	Costs And Expenses CostsAndExpenses	59379000
CY2013	us-gaap	Costs And Expenses CostsAndExpenses	48048000
CY2015Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	90000
CY2014Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	76000
CY2015Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2668000
CY2015Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	207876000
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-43019000
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-15164000
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	4901000
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-14621000
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2105000
CY2015Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	18607000
CY2015	us-gaap	Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions	15655000
CY2015	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1
CY2014Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	187153000
CY2015Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet
CY2014Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	142836000
CY2015Q4	us-gaap	Deferred Tax Liabilities Unrealized Currency Transaction Gains DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains	2668000
CY2014Q4	us-gaap	Deferred Tax Liabilities Unrealized Currency Transaction Gains DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains	2285000
CY2015	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	366000
CY2014	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	361000
CY2013	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	313000
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	180000
CY2014	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	177000
CY2013	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	304000
CY2015Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.07
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2015Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.59
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.68
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	135922000
CY2015Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2590000
CY2014Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1178000
CY2015Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1054000
CY2014Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1073000
CY2015Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	48551000
CY2014Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	38096000
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	8605000
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	7086000
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	205208000
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	184868000
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.55
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.23
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
CY2014Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
CY2015Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.06
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
CY2015Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	424000
CY2014	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-27000
CY2013	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	47000
CY2015	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	1090000
CY2014	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	5487000
CY2013	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	5294000
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
CY2015	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	20339000
CY2014	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	17312000
CY2013	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	8567000
CY2015	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	1012000
CY2014	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	22000
CY2013	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	1892000
CY2015	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-15057000
CY2014	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-15816000
CY2013	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-10538000
CY2015	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	560000
CY2014	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	258000
CY2013	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	738000
CY2015	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-218000
CY2014	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-115000
CY2013	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1144000
CY2015	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-819000
CY2014	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1286000
CY2013	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-839000
CY2015	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	10454000
CY2014	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	748000
CY2013	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1206000
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	14393000
CY2014	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	6818000
CY2013	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2049000
CY2015	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1199000
CY2014	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	4429000
CY2013	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1103000
CY2015	us-gaap	Increase Decrease In Derivative Assets IncreaseDecreaseInDerivativeAssets	-564000
CY2014	us-gaap	Increase Decrease In Derivative Assets IncreaseDecreaseInDerivativeAssets	5487000
CY2013	us-gaap	Increase Decrease In Derivative Assets IncreaseDecreaseInDerivativeAssets	5294000
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	929000
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	683000
CY2013	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1207000
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1943000
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	620000
CY2015	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-3247000
CY2015	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	1462000
CY2014	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-1000
CY2013	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-157000
CY2015Q4	us-gaap	Inventory Net InventoryNet	1612000
CY2014Q4	us-gaap	Inventory Net InventoryNet	683000
CY2014	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	7375000
CY2013	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-2447000
CY2015	us-gaap	Interest And Other Income InterestAndOtherIncome	535000
CY2014	us-gaap	Interest And Other Income InterestAndOtherIncome	93000
CY2013	us-gaap	Interest And Other Income InterestAndOtherIncome	93000
CY2015	us-gaap	Interest Expense InterestExpense	5200000
CY2014	us-gaap	Interest Expense InterestExpense	4998000
CY2013	us-gaap	Interest Expense InterestExpense	4778000
CY2015Q4	us-gaap	Interest Payable Current InterestPayableCurrent	6746000
CY2014Q4	us-gaap	Interest Payable Current InterestPayableCurrent	6029000
CY2015Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves
CY2014Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	416000
CY2015Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1612000
CY2014Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	267000
CY2015Q4	us-gaap	Investments And Cash InvestmentsAndCash	100858000
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	124555000
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	136874000
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	64453000
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	57293000
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	5479000
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	111907000
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	30270000
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-18004000
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-39980000
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-3467000
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-13116000
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-38551000
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-26530000
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-30108000
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-45189000
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	-18135000
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-10137000
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-14649000
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-8731000
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	-11672000
CY2015Q4	us-gaap	Notes Payable Current NotesPayableCurrent	30000000
CY2014Q4	us-gaap	Notes Payable Current NotesPayableCurrent	30000000
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-39444000
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-45771000
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-30717000
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	6908000
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	651000
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	651000
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	820000
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	870000
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	871000
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	3045000
CY2015	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	664000
CY2014	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	633000
CY2013	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	526000
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4522000
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4282000
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5468000
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6031000
CY2013	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-23000
CY2014	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-134000
CY2015	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-76000
CY2015	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-76000
CY2014	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-134000
CY2013	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-23000
CY2015	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	53830000
CY2014	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	73875000
CY2013	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	23974000
CY2015	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	5122000
CY2014	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	106000
CY2013	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	30000
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4870000
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6172000
CY2015	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Reclassifications</div></div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"> </div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">Long term deferred rent as of December 31, 2014 has been reclassified to conform to the 2015 presentation.</div></div></div></div></div></div></div></div></div>
CY2014Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	115000000
CY2013Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	18500000
CY2012	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	17805000
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	106600000
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	23633000
CY2013	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	5218000
CY2014Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	107800000
CY2015	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	42410000
CY2014	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	34000000
CY2013	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	20330000
CY2015	us-gaap	Proceeds From Sale Of Furniture And Fixtures ProceedsFromSaleOfFurnitureAndFixtures
CY2014	us-gaap	Proceeds From Sale Of Furniture And Fixtures ProceedsFromSaleOfFurnitureAndFixtures
CY2013	us-gaap	Proceeds From Sale Of Furniture And Fixtures ProceedsFromSaleOfFurnitureAndFixtures	50000
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5124000
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4997000
CY2013	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1333000
CY2015	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	355000
CY2014	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	310000
CY2013	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	124000
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	19354000
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14232000
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5149000
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	207000
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	28000
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	3277000
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1965000
CY2015Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	6243000
CY2014Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	3849000
CY2014	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax	0
CY2015	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax	13000
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	72758000
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	51796000
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	41943000
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1612000
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	150000
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-510917000
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-467898000
CY2015	us-gaap	Revenues Revenues	48257000
CY2014	us-gaap	Revenues Revenues	13608000
CY2013	us-gaap	Revenues Revenues	17331000
CY2015	us-gaap	Royalty Expense RoyaltyExpense	528000
CY2014	us-gaap	Royalty Expense RoyaltyExpense	121000
CY2013	us-gaap	Royalty Expense RoyaltyExpense	98000
CY2015	us-gaap	Royalty Revenue RoyaltyRevenue	2386000
CY2014	us-gaap	Royalty Revenue RoyaltyRevenue	3025000
CY2013	us-gaap	Royalty Revenue RoyaltyRevenue	2562000
CY2015	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	6291000
CY2014	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	33000
CY2013	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet
CY2015	us-gaap	Sales Revenue Net SalesRevenueNet	48257000
CY2014	us-gaap	Sales Revenue Net SalesRevenueNet	13608000
CY2013	us-gaap	Sales Revenue Net SalesRevenueNet	17331000
CY2015Q1	us-gaap	Sales Revenue Net SalesRevenueNet	6826000
CY2015Q2	us-gaap	Sales Revenue Net SalesRevenueNet	25842000
CY2015Q3	us-gaap	Sales Revenue Net SalesRevenueNet	10987000
CY2015Q4	us-gaap	Sales Revenue Net SalesRevenueNet	4602000
CY2014Q1	us-gaap	Sales Revenue Net SalesRevenueNet	3458000
CY2014Q2	us-gaap	Sales Revenue Net SalesRevenueNet	1466000
CY2014Q3	us-gaap	Sales Revenue Net SalesRevenueNet	3238000
CY2014Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	11500000
CY2013Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	4600000
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	9.87
CY2014Q4	us-gaap	Sales Revenue Net SalesRevenueNet	5446000
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2217000
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.72
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8073000
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	2217000
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8986000
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9605000
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10671000
CY2015	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13047000
CY2014	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7461000
CY2013	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6007000
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	9705000
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	10177000
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	4368000
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	53000
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	1000
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	310000
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	593000
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	163000
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.81
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.87
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.84
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.016
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.016
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.007
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2815000
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1082000
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2362000
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	16000
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.99
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.21
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.50
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	1801000
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	88000
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	33000
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	7.22
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	8.83
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.09
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Other Share Increase Decrease ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease	3750000
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.37
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.78
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.36
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.05
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	10.99
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	11.52
CY2015Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	5700
CY2015Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	6700
CY2015	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit	10671
CY2013Q3	us-gaap	Share Price SharePrice	4.40
CY2012Q4	us-gaap	Share Price SharePrice	4.08
CY2013Q4	us-gaap	Share Price SharePrice	1.85
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y182D
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y182D
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y255D
CY2014Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	4385000
CY2015Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	4863000
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	6.39
CY2014Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	4.27
CY2015Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	6.40
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	1711000
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	2.63
CY2015Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	5809
CY2015	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P7Y182D
CY2012	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	4516000
CY2013	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	2883000
CY2013	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	563000
CY2014	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1258000
CY2015	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1118000
CY2013	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	124000
CY2014	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	310000
CY2015	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	355000
CY2013	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	23634000
CY2014	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	106600000
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1333000
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4997000
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5124000
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	-454000
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-1126000
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	75635000
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	47724000
CY2015Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	102000
CY2014Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	75000
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	472000
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	284000
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3085000
CY2015	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
CY2014	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	12000
CY2015Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2014Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2013Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2616000
CY2014	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	176000
CY2015	us-gaap	Use Of Estimates UseOfEstimates	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"> </div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates. </div></div></div></div></div></div></div></div></div>
CY2015	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	72901000
CY2014	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	66773000
CY2013	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	55216000

Files In Submission

Name	View Source	Status
0001171843-16-008207-index-headers.html	Edgar Link	pending
0001171843-16-008207-index.html	Edgar Link	pending
0001171843-16-008207.txt	Edgar Link	pending
0001171843-16-008207-xbrl.zip	Edgar Link	pending
bcrx-20151231.xml	Edgar Link	completed
bcrx-20151231.xsd	Edgar Link	pending
bcrx-20151231_cal.xml	Edgar Link	unprocessable
bcrx-20151231_def.xml	Edgar Link	unprocessable
bcrx-20151231_lab.xml	Edgar Link	unprocessable
bcrx-20151231_pre.xml	Edgar Link	unprocessable
exh1070_1.jpg	Edgar Link	pending
exh1070_2.jpg	Edgar Link	pending
exh1070_3.jpg	Edgar Link	pending
exh1070_4.jpg	Edgar Link	pending
exh1071_1.jpg	Edgar Link	pending
exh1071_2.jpg	Edgar Link	pending
exh1071_3.jpg	Edgar Link	pending
exh_1070.htm	Edgar Link	pending
exh_1071.htm	Edgar Link	pending
exh_21.htm	Edgar Link	pending
exh_23.htm	Edgar Link	pending
exh_311.htm	Edgar Link	pending
exh_312.htm	Edgar Link	pending
exh_321.htm	Edgar Link	pending
exh_322.htm	Edgar Link	pending
f10k_022616p.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
graph.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx

2014 Q4 Form 10-K Financial Statement

#000117184316008207 Filed on February 26, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCRX BIOCRYST PHARMACEUTICALS INC Stock $bcrx

2014 Q4 Form 10-K Financial Statement

#000117184316008207 Filed on February 26, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx